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Abstract
Purpose The aim of this study was to determine whether clinical outcome after surgical resection of esophageal
adenocarcinoma (EAC) or esophageal squamous cell carcinoma (ESCC) could be predicted by functional polymorphisms in
different proto-oncogenes and tumor suppressor genes.
Experimental Design Six single nucleotide polymorphisms (SNPs) in the AURKA (rs2273535), ERBB2 (rs1136201),
MDM2 (rs2279744), CDH1 (rs5030625), CDKN2A (rs11515), and TP73 (rs2273953) genes were genotyped in a
consecutive cohort of 346 esophageal cancer patients, who had underwent surgical resection with curative intent.
Associations with disease-free survival (DFS) were analyzed with Kaplan–Meier curves and Cox regression, adjusting for
potential confounders.
Results Univariate analysis showed no significant associations between the tested polymorphisms and DFS in patients with
EAC or ESCC. However, in a multivariate analysis, patients with EAC carrying the heterozygous MDM2 (rs2279744) T/G
genotype had significantly improved DFS compared with patients carrying the wild-type genotype (adjusted hazard ratio
(AHR), 0.63; 95% confidence interval (CI) [0.45–0.88]). Patients with EAC harboring the homozygous CDH1 (rs5030625)
GA/GA genotype had a significantly reduced survival as compared with patients carrying the wild-type genotype AHR 4.0,
95% CI [1.4–11].
Conclusions In a large cohort of esophageal cancer patients, the MDM2 T/G and CDH1 GA/GA genotype confer risk of
death in patients with EAC. These data suggest that inter-individual differences in germ-line DNA have an impact on DFS
in patients with EAC.
Keywords Esophagus . Adenocarcinoma . Squamous cell
carcinoma . Polymorphism . SNP
Introduction
Many therapeutic options are used to treat esophageal
cancer, but traditionally, surgery is used most frequently to
obtain loco-regional control and long-term survival.1,2
Comprehensive preoperative staging has improved selec-
tion of patients for potentially curative surgery; however,
many patients present with recurrent disease within 2 years
after operation. The majority of these patients develop not
only loco-regional recurrences, but also distant metastases
(such as liver, lung, pleural, and/or peritoneal disease
recurrences) are common.3–5 Despite attempts to improve
the outcome of patients with esophageal cancer, prognosis
remains poor with a 5-year overall survival of 20–30%.5,6
Well-known prognostic factors for esophageal cancer are
summarized in tumor node metastasis (TNM) staging.7,8
Although TNM parameters have the advantage of simplic-
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ity, they do not seem to completely reflect the biologic
diversity of esophageal cancer.9,10 The true drivers of this
clinical biologic diversity include the molecular aberrations
of the cancer and the genetic make-up of the patient. In this
respect, the study of host genetic variability offers worth-
while potential to identify individuals that may have the
best chance of survival. Single nucleotide polymorphisms
(SNPs) in the germ-line are the most common type of host
genetic variations. Gene-related functional SNPs can
potentially lead to differences in protein expression and/or
function. In this way, SNPs in proto-oncogenes and tumor
suppressor genes can potentially alter the risk for metastatic
or aggressive tumor, resulting in differences in clinical
outcome.
Altered expression of the AURKA, ERBB2, MDM2,
CDH1, CDKN2A, and TP73 proteins has been correlated to
disease progression and clinical outcome in patients with
esophageal cancer.11–17 In addition, polymorphisms with
effects on protein function have been identified in these
proto-oncogenes and tumor suppressor genes.18–23 Based
on these results, we postulated that functional SNPs in the
AURKA (AURKA_NM_003600.2; rs2273535 c.449 T>A),
ERBB2 (ERBB2_NM004448.2; rs1136201 c.655 A>G),
MDM2 (MDM2_NM002392.2; rs2279744 309 T>G),
CDH1 (CDH1_NM004360.3; rs5030625 -347 G>GA),
CDKN2A (CDKN2A_NM000077.3; rs11515 c.712 C>G),
and TP73 (TP73_NM005427.1; rs2273953 81 G>A) genes
may serve as molecular markers for clinical outcome in
patients with esophageal adenocarcinoma (EAC) or esoph-
ageal squamous cell carcinoma (ESCC) who underwent
surgical resection.
Patients and Methods
Patients Between 1996 and 2001, a total of 632 consecu-
tive patients with esophageal cancer were evaluated for
surgery with curative intent at the Erasmus University
Medical Center (Fig. 1). Outcome for all patients with
esophageal cancer referred to our hospital are collected
Fig. 1 Flowchart of patients with esophageal cancer referred to the Erasmus MC for treatment between January 1996 and December 2001.
Patients excluded from the present study are shown
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prospectively and stored in a database by a data manager.
The data collected encompassed all relevant diagnostic
tests, scheduled treatments, and pathology. All patients
were staged using esophago-gastroscopy with biopsies,
ultrasonography of the cervical and upper abdominal
region, and computed tomography of the thorax and
abdomen. Endoscopic ultrasonography for evaluation of
T-stage and nodal status was routinely performed.
Surgery For carcinomas of the upper half of the intra-
thoracic esophagus, a right-sided thoracotomy was per-
formed. For carcinomas of the lower half of the intra-
thoracic esophagus, a transhiatal esophagectomy was
preferred. The tumor and its adjacent lymph nodes were
dissected en bloc; however, no extended lymph node
dissection was performed. The continuity of the digestive
tract was restored by means of a gastric tube reconstruction
or colonic interposition with a cervical anastomosis.
Resections were considered radical (R0) if microscopic
examination revealed no tumor tissue at or less than 1 mm
from the circumferential, proximal, or distal margins.
Pathological staging was done according to the Union for
International Cancer Control (UICC) sixth edition. The
tumor stage after resection was classified according to the
TNM classification of the International Union Against
Cancer.
SNP Genotyping To determine the individual genotype for
each SNP, genomic DNA was extracted from frozen or
formalin-fixed and paraffin-embedded (FFPE) tissues.
Normal tissue was obtained from the resection specimens
(i.e., tumor-negative lymph nodes or tumor-negative resec-
tion margins). All the archival tissue samples were used
according to the code for adequate secondary use of tissue,
code of conduct: “Proper Secondary Use of Human Tissue”
established by the Dutch Federation of Medical Scientific
Societies (http://www.federa.org).
Polymerase chain reactions (PCR) were carried out in
a volume of 15 μl containing genomic DNA, 8.3 μl
H2O, 5 μl Mg
2+free buffer, 25 mM MgCl2, 0.3 μl of
10 mM deoxynucleotide triphosphates, 20 pmol of each
primer, and 1 U Taq polymerase (Promega, Madison WI,
USA). PCR conditions were standardized at 35 cycles of
95°C for 45 s, 61°C for 45 s, 72°C for 30 s, with a 10-min
extension at 72°C for 10 min following the last cycle. PCR
primers for each SNP are shown in Table 1. For the
polymorphism in CDH1 (rs5030625), amplified PCR
products were visualized on a denaturing polyacrylamide
gel. For detection of the restriction length polymorphisms
in ERBB2 (rs1136201) and AURKA (rs2273535), PCR
products were digested for 16 h at the appropriate
temperature with10 U of restriction endonuclease BsmAI,
MspI, or APOI (Promega, Madison, WI, USA), respec- Ta
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Table 2 Survival according to patients’ and tumor characteristics
Variable Patients with EAC (N=214) Patients with ESCC (N=97)
No. (%) Median DFS P values No. (%) Median DFS P values
Age in years 0.23 0.33
<65 years 111 (52) 19 64 (66) 21
≥65 years 103 (48) 12 33 (34) 12
Gender 0.41 0.44
Male 182 (85) 16 58 (60) 15
Female 32 (15) 11 39 (40) 20
Weight loss before operation 0.013 0.47
No loss or <5% 127 (59) 19 46 (47) 15
5–10% 35 (16) 11 31 (32) 27
>10% 32 (15) 8 17 (18) 10
Not recorded 20 (10) 10 3 (3) 5
Smoking status 0.98 0.70
Current smoker 54 (25) 14 43 (44) 16
No current smoker 146 (68) 15 47 (49) 20
Not recorded 14 (7) 8 7 (7) 4
Location of tumor 0.150 0.008
Upper one third thoracic esophagus 3 (3) 4
Middle one third thoracic esophagus 3 (1) 11 39 (40) 12
Lower one third thoracic esophagus 68 (32) 24 45 (47) 20
GEJ 86 (40) 13 10 (10) 60
Gastric cardia 57 (27) 12
Tumor length (cm) 0.028 0.27
0–2 34 (16) 41 8 (8) 37
3–4 52 (24) 15 24 (25) 10
4–5 67 (31) 14 31 (32) 24
≥6 46 (22) 9 25 (26) 9
Not recorded 15 (7) 16 9 (9) 11
Barrett’s epithelium 0.086
No 127 (59) 12
Yes 87 (41) 24
Treatment 0.83 0.18
Surgery alone 180 (84) 14 28 (29) 8
Chemotherapy+surgery 23 (11) 15 65 (67) 15
Chemoradiotherapy+surgery 11 (5) 21 4 (4) Not reached
Resection type 0.83 0.042
Transhiatal 187 (87) 15 53 (55) 37
Transthoracic 27 (13) 9 44 (45) 11
Post-operative UICC stage <0.001 <0.001
Complete response 8 (4) 40 13 (13) Not reached
I 24 (11) 98 13 (13) 86
IIA 43 (20) 37 34 (35) 12
IIB 8 (4) 15 4 (4) 26
III 74 (34) 11 17 (18) 8
IV 57 (27) 7 16 (17) 4
Radicality of resection <0.001 <0.001
R0 141 (66) 34 65 (67) 41
R1 70 (33) 7 29 (30) 6
R2 3 (1) 9 3 (3) 5
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tively. The DNA fragments were separated using 3%
agarose gels. The polymorphisms in CDKN2A (rs11515),
MDM2 (rs2279744), and TP73 (rs2273953) were geno-
typed by bi-directional sequencing.
Statistical Analysis Data on follow-up were collected from
the prospective database and the medical charts. All
patients were followed at an interval of 3 to 4 months
during the first year, every 6 months for the second year,
and then at the end of each year until 5 years after
treatment. Recurrence or disease progression was diag-
nosed on clinical grounds. Whenever a relapse was
suspected, radiologic, endoscopic, or histologic confir-
mation was sought. Recurrent disease was classified as
local–regional (occurring in the upper abdomen or
mediastinum) or distant (including cervical recurrences).
Study end-point was disease-free survival (DFS) that
was defined as the time from surgery until recurrent
disease or death from any cause. The Kaplan–Meier survival
function and log-rank tests were used to assess clinical
outcome in relation to patient’s characteristics and individual
polymorphisms. Cox proportional hazard ratios for patients
with EAC were adjusted for weight loss prior to operation,
tumor length, presence of Barrett’s epithelium, radicality of
resection, and pathological tumor stage. For patients with
ESCC, Cox proportional hazard ratios were adjusted for
location of tumor, resection type, post-operative TNM stage,
and radicality of resection. Statistical significance was set at
the 5% level. We did not adjust for multiple testing since each
gene outcome was prespecified and of interest in itself.
Results
Patients A total of 346 esophageal cancer patients under-
went surgical resection with curative intent. Of these, 25
Table 3 Polymorphisms and clinical outcome in patients with resected EAC
Genotype Disease-free survival in EAC patients Disease-free survival in ESCC patients
N MPS (months) Log-rank P AHR [95% CI]a N MPS (months) Log-rank P AHR [95% CI]b
AURKA_rs2273535
T/T 129 15 0.83 Reference 62 12 0.72 Reference
A/T 75 14 1.1 [0.76–1.4] 29 20 0.60 [0.17–2.1]
A/A 9 21 0.92 [0.42–2.0] 5 55 0.63 [0.18–2.1]
ERBB2_rs1136201
A/A 113 14 0.25 Reference 66 12 0.66 Reference
A/G 86 15 0.92 [0.67–1.3] 23 26 0.73 [0.41–1.3]
G/G 14 12 0.68 [0.33–1.4] 6 8 1.3 [0.49–3.2]
MDM2_rs2279744
T/T 100 11 0.076 Reference 40 10 0.63 Reference
T/G 84 19 0.63 [0.45–0.88] 45 21 0.98 [0.59–1.6]
G/G 24 12 0.95 [0.58–1.6] 7 16 0.81 [0.28–2.4]
CDH1_rs5030625
G/G 166 17 0.14 68 11 0.13 Reference
G/GA 41 11 1.2 [0.78–1.7] 18 27 0.63 [0.32–1.3]
GA/GA 4 7 4.0 [1.4–11] 1 Not reached
CDKN2A_rs11515
C/C 162 13 0.79 Reference 74 12 0.67 Reference
C/G 47 19 0.94 [0.65–1.3] 20 20 0.67 [0.36–1.3]
G/G 4 19 1.7 [0.52–5.6] 1 Not reached
TP73_rs2273953
G/G 138 16 0.44 Reference 62 24 0.48 Reference
G/A 69 13 0.98 [0.71–1.4] 32 10 1.1 [0.66–1.8]
A/A 5 11 1.1 [0.41–3.1] 2 4 1.7 [0.40–7.3]
a Adjusted hazard ratio for weight loss prior to operation, tumor length, presence of Barrett’s epithelium, post-operative TNM stage, and radicality of
resection
b Adjusted hazard ratio for location of the tumor, type of resection, post-operative TNM stage, and radicality of resection
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patients were excluded from the current follow-up study
because no tissue samples were available (N=9), genotyp-
ing failure (N=3), or incomplete follow-up (N=13) (Fig. 1).
Of the 214 EAC and 97 ESCC patients remaining for
analysis, the majority were male, 85% in EAC and 60% in
ESCC. Median age at time of diagnosis was 64 and
61 years, respectively. Of all patients with EAC, 84%
underwent primary surgery and 16% received preoperative
Fig. 2 a Kaplan–Meier analysis of DFS in patients with esophageal cancer, by histological subgroup. b Kaplan–Meier analysis of DFS in patients
with EAC, by MDM2 (rs2279744). c Kaplan–Meier analysis of DFS in patients with EAC, by CDH1 genotype (rs5030625)
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chemotherapy with or without radiotherapy. In contrast,
71% of patients with ESCC received preoperative chemo-
therapy with or without radiotherapy and 29% underwent
primary surgical resection (Table 2).
SNP Genotyping Genotyping was complete in 95% to
100% of EAC and ESCC patients. The genotype distribu-
tions did not deviate from HWE (P>0.05). The genotype
distribution of each SNP is listed in Table 3. Tumor stage
distributions were similar across all SNP genotypes, and
there was no association between genotypes and age at
diagnosis, sex, weight loss, smoking status, or preoperative
treatment.
DFS and Pattern of Disease Recurrence The median DFS
of EAC patients was 14 months (range, 0.07–138 months)
and for ESCC patients 16 months (range, 0.5–148 months).
At the time of analysis, 37 (17%) EAC and 27 (28%) ESCC
patients were alive with a median DFS time of 93 months
(range, 62–138 months) and 104 months (range 79–
148 months), respectively (Fig 2A).
The pattern of disease recurrence is depicted in Table 3.
Loco-regional recurrences were mediastinal or abdominal
lymph node metastases and recurrences in the gastric tube.
Distant metastases were found in liver, lung, brain, bone,
adrenal gland, pleura, peritoneum, and skin.
Recurrent disease after surgery was found in 138 (78%)
EAC patients; 40 patients had loco-regional recurrence, 51
had distant metastasis, and 46 had both loco-regional
recurrence and distant metastasis. One patient had disease
recurrence, but the site of failure was not recorded. Diseases
recurrences were found in 51 ESCC patients; 28 patients
had loco-regional recurrence, 10 had distant metastasis, and
10 had both loco-regional recurrence and distant metastasis.
Three patients had disease recurrence, but site of failure
was not recorded.
SNP Genotype and DFS Univariate analysis showed no
significant associations between DFS in patients with EAC
or ESCC and the genotype distributions of the AURKA,
ERBB2, MDM2, CDH1, CDKN2A, and the TP73 gene
polymorphisms (Table 4; Fig 2B and C). However, in a
multivariate analysis, patients with EAC carrying the
heterozygous MDM2 (rs2279744) T/G genotype had
significantly improved DFS compared with patients carry-
ing the wild-type T/T genotype (adjusted hazard ratio
(AHR) 0.63, 95% confidence interval (CI) [0.45–0.88], P=
0.007). The post-operative TNM stage of the tumor and the
radicality of resection were also found important factors for
DFS (HR 1.4, 95% CI [1.2–1.6], P<0.0001 and HR 2.3,
95%CI [1.7–3.1], P<0.0001 respectively).
Also, patients with EAC harboring the homozygous
CDH1 (rs5030625) GA/GA genotype had a significantly
reduced survival as compared with patients carrying the
wild-type G/G genotype AHR 4.0, 95% CI [1.4–11], P=
0.008. In multivariate analysis, the post-operative TNM
stage of the tumor and the radicality of resection were
found as important factors for DFS (HR 1.4, 95% CI [1.2–
1.5], P<0.0001 and HR 2.4, 95%CI [1.7–3.2], P<0.0001
respectively).
Discussion
In the present study, we determined the relationship
between inter-individual DNA variations in six bona fide
proto-oncogenes and tumor suppressor genes and DFS in a
large cohort of Caucasian patients with esophageal cancer.
After adjustment for potential confounders, the variant
genotypes of SNPs located in the promoter region of the
MDM2 and CDH1 gene were significantly associated with
DFS in patients with EAC.
The results of the present study showed a significant
survival benefit for patients harboring the MDM2 T/G as
compared with patients carrying the wild-type T/T genotype.
The MDM2 protein is a nuclear phosphoprotein that binds
and inhibits the tumor suppressor TP53 as part of an
autoregulatory negative feedback loop. The most intensively
characterized MDM2 polymorphism is the T309G promoter
SNP located in the first intron.20 The G variant of this SNP is
known to increase promoter-binding affinity, leading to up-
regulation of MDM2 and consequent inhibition and down-
regulation of the p53 pathway. Therefore, it could be
expected that the variant MDM2 genotypes (T/G and G/G)
Table 4 Pattern of failure
EAC (N=214) ESCC (N=97)
Alive 37 (17) 27 (28)
Nature of first failure
Local recurrence 40 (29) 28 (55)
Distant metastases 51 (37) 10 (20)
Local recurrence and
distant metastases
46 (33) 10 (20)
Disease recurrence but
site of failure not reported
1 (1) 3 (5)
Total deaths 177 (83) 70 (72)
Cause of death
Cancer-related 138 (78) 51 (71)
Surgery-related 14 (8) 7 (11)
2nd Primary 5 (3) 6 (8)
Death from other cause
(not cancer-related)
20 (11) 6 (8)
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are associated with adverse outcome in esophageal cancer
patients (as shown in other cancer types).24 However, the
present study showed improved survival in patients with the
MDM2 T/G genotype compared with the wild-type T/T
genotype. A possible explanation for our findings is
provided by a large study in breast cancer patients that
reported strong interaction between the MDM2 SNP status
and tumor TP53 status, which appeared to modify the
association between TP53 status and breast cancer survival.25
Among breast cancer patients with the wild-type MDM2
genotype (T/T), a mutant TP53 status and aberrant TP53
expression in breast tumors were associated with poor
survival. The tumor TP53 status was not associated with
breast cancer survival among carriers of the variant
MDM2 allele (T/G or G/G). Since TP53 is the most
frequently mutated gene in EAC, it could be hypothesized
that the tumors of most patients with the T/T genotype
harbor a TP53 mutation, which could lead to a reduced
survival as observed in the present study. In a previously
well-conducted study, the known TP53 codon 72 Arg/Pro
and MDM2 polymorphisms were genotyped in 300
patients with EAC and 63 patients with ESCC.26 As in
concordance with the results of the present study, patients
with EAC harboring the MDM2 T/G genotype had a
borderline improved overall survival as compared with
patients carrying the wild-type genotype (AHR for death
0.70, 95% CI [0.50–0.99], P=0.04). But unlike the present
study, the MDM2 variant genotype did correlate with
marked reduced survival in patients with ESCC. This
could be due to differences in study samples size,
population selection, tissue handling, and genotyping
methods.
In this study, patients carrying the CDH1GA/GA genotype
had a significantly reduced survival as compared with patients
with the wild-type G/G genotype. However, it should be noted
that only four EAC patients carried the GA/GA genotype,
which may represents a chance finding. Nevertheless, this
-347 G/GA insertion polymorphism located in the promoter of
the cell–cell adhesion gene CDH1 has been reported to
suppress CDH1 gene expression and was found to be
associated with familial gastric cancer and sporadic
colorectal cancer.27 The GA-allele has been associated
with significant suppression of CDH1 promoter activity in
colorectal and gastric cancer cell lines.27 It can be
hypothesized that the GA-allele might enhance the progres-
sion of esophageal cancer by reducing CDH1 transcription
resulting in a decrease in CDH1 protein expression and
impairment of cell–cell adhesion. All four patients harboring
the GA/GA genotype died of recurrent disease; three had
loco-regional and distant metastasis, and one had only loco-
regional disease recurrence.
To our knowledge, this is one of the first studies that
investigated the relationship between polymorphisms
and esophageal cancer outcome. Here, we studied
(only) six polymorphisms, whereas SNP arrays can
determine more than a million of SNPs in one sample.
Although this technique is widely used on blood or fresh
frozen samples, it is not very suitable for FFPE tissue samples
(our series consisted primarily of FFPE samples). Therefore,
collection of blood samples or fresh frozen tissue samples of
esophageal cancer patients is necessary and should become
standard procedure in order to perform genome-wide associ-
ation studies. In this study, the majority of polymorphisms
were not associated with DFS after esophagectomy. It
could be well that our study, among a relatively large
population (N=346) of esophageal cancer patients, failed
to observe a difference due to under powering. Since
esophageal cancer has a relatively low incidence, consortia (of
multiple hospitals) are needed to validate these associations.
Recurrent cancer is the leading cause of death in patients
undergoing surgical resection.3–5 Although treatment
options for esophageal cancer recurrences are limited, it
could be proposed that early detection of recurrent disease
is desirable because aggressive treatment may result in
prolonged tumor-free survival or occasional cure. In this
light, our findings could contribute to the identification of
patients who are at high or low risk for the development of
disease recurrences. It can also be proposed that patients
with a certain genetic constitution that is associated with a
high chance of (distant) disease recurrence should be given
systemic adjuvant treatment after surgical resection.
Furthermore, identification of polymorphisms associated with
DFS could serve well as hypothesis generating for prospective
studies that evaluate the prognostic significance of germ-line
variants.
In summary, our results indicate that two of six
investigated functional polymorphisms are associated with
DFS in patients who underwent esophagectomy for EAC.
Patients with EAC carrying the heterozygous MDM2 T/G
genotype had twofold reduced risk of disease recurrence,
and patients with the homozygous CDH1 GA/GA had a
fourfold increased risk of disease recurrence. Additional
prospective studies are necessary to validate both associa-
tions and to study the prognostic significance of both germ-
line variants.
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